Search
iniparib
Indications:
- improves outcomes in triple-negative* breast cancer when administered alongside standard chemotherapy
- androgen-independent metastatic prostate cancer
* estrogen receptor negative, progesterone receptor negative, HER2 negative
Mechanism of action:
- inhibits poly(ADP)ribose polymerase (PARP), thus DNA repair of single-strand breaks
- unrepaired single strand breaks become double-strand breaks
- breast cancer patients with loss of BRCA1 or BRCA2 function are deficient in DNA double-strand break repair
- thus the PARP inibitor iniparib shows selective toxicity for tumor cells with homozygous BRCA1 or BRCA2 dysfunction
General
small inhibitory antineoplastic agent (ib drug)
PARP inhibitor
Database Correlations
PUBCHEM cid=9796068
References
- O'Shaughnessy EC et al
Iniparib plus Chemotherapy in Metastatic Triple-Negative
Breast Cancer
N Eng J Med January 5, 2011
PMID: 21208101
http://www.nejm.org/doi/full/10.1056/NEJMoa1011418
- Carey LA and Sharpless NE
PARP and Cancer - If It's Broke, Don't Fix It
N Eng J Med January 5, 2011
PMID: 21208102
http://www.nejm.org/doi/full/10.1056/NEJMe1012546